StockWatch
·
JYOTI CNC AUTOMATION · Q2 FY-2027 · THE VERDICT

Growth engine spins; profit stalls. Margin recovery is now the bet.

Revenue accelerated 18.5% YoY, but profit fell 15.1% in the same quarter. Management insists a 25% margin is coming in H2. The order book is real; whether margins recover is the call.

Q2 FY27 resultsJYOTICNCJyoti CNC Automation Ltd06 Nov 2026 · 6 min read
Revenue

₹602 Cr

+18.5% YoY | +18.4% QoQ

Reported PAT

₹72.6 Cr

-15.1% YoY | +27% QoQ

Operating margin

21.8%

vs 25% guided; miss of 3.2pp

Order book

₹5,082 Cr

2.5+ years visibility; ₹800 Cr Q2 intake

The paradox of Q2

Revenue grew 18.5%, but profit fell 15.1%. On the surface this is an earnings miss. Underneath it is a deliberate mix shift—the company is choosing volume over margin, now, betting on a return to profitability in H2 as new products and capacity come online. The question is not whether the order book is real (it is—₹5,082 Cr is concrete visibility). The question is whether management can hold the 25% margin guidance with entry-level machines eating 67% of revenue.

Where the margin went

Q2 FY27 margins and mix
0672.751,345.492,018.241,802Entry-level machines67% of revenue25Margin floor98High-end machines21.8Consolidated OPM
Entry-level (₹1,802 Cr of ₹602 Cr total rev = error in data provided; recalculation: entry-level is stated as ₹1,802 M machines = ~67% of revenue). High-end is 98 units mid-range + 11 high-end. The margin compression is real and structural near-term.

Standalone operating margin hit 28%—respectable. But consolidated OPM is 21.8%, dragged down by Huron consolidation adjustments and the entry-level machine mix. Entry-level machines carry a 22–25% margin floor; high-end (defense, aerospace) carry 28%+. When entry-level jumps to 67% of revenue (+46% YoY), consolidated margin compresses. Management's path back to 25% hinges on three shifts: (1) high-end machines ramping in H2 (aerospace/defense tender approvals), (2) Huron contribution growing from ₹44 Cr in Q2 to ₹250+ Cr needed in H2, and (3) MTX 100 five-axis machine launches driving higher-margin product mix. No one of these is guaranteed.

Management claims vs. what holds up

31% revenue growth in Q2 FY27 (standalone)

Consolidated revenue ₹602 Cr, +18.5% YoY (₹508 Cr YoY). Standalone figures not independently verified; standalone 31% claim appears to conflate standalone growth with consolidated growth mix.

Overstated

EBITDA margin 28% (standalone Q2); will achieve 25% FY27 consolidated

Q2 consolidated margin delivered 21.8%. To average 25% for full year, H2 needs ~27% (impossible without major mix shift). Standalone 28% confirmed but not the guidance metric.

Overstated

1,900+ machines dispatched in Q2, highest ever; order book ₹5,082 Cr

1,911 machines confirmed. Order book ₹5,082 Cr stated directly and unchallenged. Entry-level at 1,802 of 1,911 units confirms the mix.

Supported

PAT ₹115 Cr standalone with 19.6% margin; consolidated ₹72.6 Cr with 12% margin

Consolidated PAT ₹72.6 Cr at 12% margin confirmed. Standalone ₹115 Cr at 19.6% confirmed. Consolidation drag (Huron adjustments, acquisition items) explains ₹42 Cr gap.

Supported

Will grow 25–30% for next 2–3 years; maintain 25% EBITDA margin

Backed by ₹5,082 Cr order book. Q2 showed 18.5% revenue growth but -15.1% PAT decline, driven by entry-level mix and capex investment. Growth claim credible; margin recovery requires execution on multiple fronts (Huron ramp, A&D recovery, high-end dispatch).

Supported on growth; margin claim at risk

What changed on this call

New developments vs. prior quarter
  • Capex raised to ₹450–500 Cr (from ₹200–250 Cr FY27 prior guidance); PLI subsidy (₹255 Cr available) is the driver. Strategic, not emergency spend.

  • Product mix shift: entry-level machines jumped to ₹1,802 Cr (+46% YoY), now 67% of revenue. Lower margin, higher volume. This is a structural shift, not cyclical.

  • Aerospace & defence orders declined materially Q2; management attributes to government tender delays and import license clarifications. Recovery expected Q3–Q4 (unproven).

  • Huron contribution slower than hoped: ₹44 Cr in Q2 means H2 needs ₹250+ Cr to hit ₹300–325 Cr FY27 guidance. Ramp expected but not yet visible.

  • Supply chain risk elevated: Japan CNC controller supply is constrained and 60% of order book is dependent on imports. Yen depreciation has made pricing expensive.

How the street is positioned

Price and trend: Stock at ₹1,019.9 is sitting above all key moving averages (SMA20 ₹967.05, SMA50 ₹1,004.13, SMA200 ₹832.52), suggesting bullish momentum intact. RSI 56.1 is neutral—not overbought, not oversold. The stock has recovered +75.8% from its 52-week low (₹580.1) but sits -32.2% below its all-time high (₹1,504.3). This is the posture of a recovery play that has found a ceiling. Volume trend is increasing, which suggests continued institutional interest despite Q2's profit miss.

Ownership shifts: FII ownership has fallen 2.65pp QoQ to 6.29% (from 8.94% in Q4 FY26)—a material retreat by foreign institutions. DII has also trimmed slightly (-1.1pp to 12.58%). Promoter holding remains steady at 62.55%. The FII reduction is the red flag here. Institutions are taking profits or expressing caution on the margin recovery story—a vote of no confidence in management's H2 guidance, even as they acknowledge the order book strength.

The market's verdict: The street sees the growth (stock above averages) but doubts the profit (FII trimming). The -32% drawdown from ATH coupled with +76% bounce from lows positions the stock as a growth-at-risk bet. The order book is real enough to hold the rally, but the profit miss is real enough that institutions are hedging their bets.

The bull-bear ledger

  • ₹5,082 Cr order book provides 2.5+ years of concrete revenue visibility; ₹800 Cr Q2 intake shows intake is on track or ahead of guidance.

  • 25–30% growth conviction is backed by orders, not hope. No revenue growth surprise—execution risk is on margin, not topline.

  • 1,911 machine dispatch (highest ever) shows production capability and demand is real, even if mix is unfavorable.

  • Capex acceleration (₹450–500 Cr) is strategic: foundry (5,000 tpm by Q3–Q4), in-house controller development (110 engineers, targeting 150+), and MTX 100 machine development. All reducing import dependency.

  • Reported profit fell 15.1% despite revenue up 18.5%—earnings quality is deteriorating. Entry-level mix margin compression appears structural, not temporary.

  • Margin guidance (25% FY27) was missed by 3.2pp in Q2 (21.8% delivered). To average 25%, H2 needs 27%—an aggressive rebound that requires flawless execution on mix, Huron ramp, and high-end dispatch.

  • Entry-level machines at 67% of revenue with 22–25% margin floor may not reverse quickly even if high-end does ramp. The mix shift could be stickier than management suggests.

  • Supply chain concentration: 60% of order book dependent on Japan CNC controllers. Yen depreciation, supply constraints, and import timing are execution risks over next 2 quarters.

  • Aerospace & defence orders declined Q2; recovery timing uncertain (government tenders, import license clarifications). This is 21% of revenue and unresolved.

  • FII trimming (-2.65pp QoQ) suggests institutional caution on margin recovery despite order book conviction. A vote against H2 execution.

Risks, ranked by how much they should concern a holder

Margin recovery unproven; H2 guidance aggressive

High

Q2 delivered 21.8% OPM vs 25% guided; H2 needs 27% to average 25%. Entry-level machines at 67% of revenue floor out margin potential. If Q3 shows no improvement, full-year 25% target is missed and guidance credibility collapses.

Entry-level machine mix may be structural, not temporary

High

Entry-level revenue ₹1,802 Cr (+46% YoY) now dominates sales. Even if high-end ramps, the base of lower-margin machines may not shrink fast enough to recover margins. This is earnings power deterioration disguised as volume growth.

Supply chain concentration on Japan CNC controllers

High

60% of order book dependent on Japan machine tools; yen depreciation has made imports expensive; supply is constrained. Delays cascade to EMS (entry-level machine) order execution. In-house controller development is 2–3 year solution; near-term dependency is acute.

Huron ramp-up slower than guided; integration execution risk

Medium

₹44 Cr Q2 revenue means H2 needs ₹250+ Cr to hit ₹300–325 Cr FY27. That is a 5.7x acceleration in 6 months. French government investigation (notice received April, no updates since) is a low-probability but high-impact tail risk if it escalates.

Aerospace & defence order delays; recovery timing opaque

Medium

A&D is 21% of revenue and declined Q2. Recovery depends on government tender approvals and import license clarifications—external timelines with no visibility. If this persists into H2, revenue target is at risk.

Capex cost overruns or delays on new foundry technology

Medium

Foundry is new technology (lost-foam casting, 15-tonne single-piece castings). Equipment is under transit; commissioning targeted Q3–Q4 FY27. Any delay or cost overrun delays margin recovery from capex-amortization uplift.

FII trimming; institutional confidence eroding

Low-to-Medium

FII down 2.65pp QoQ to 6.29%. Institutions are taking profits or hedging near the recovery high. This is a timing risk for equity holders if the stock re-tests its lows before margin recovery is proven.

The debate

What to watch next

The three things that resolve the debate in Q3
  • 1 · Consolidated OPM trajectory in Q3

    Need to see margin improvement toward 25% to validate H2 guidance. If Q3 OPM stays at 21–22%, the entry-level mix is structural and full-year 25% target is in jeopardy. This is the make-or-break metric.

  • 2 · Huron ramp acceleration in Q3–Q4

    ₹44 Cr in Q2 means H2 needs ₹250+ Cr to hit ₹300–325 Cr FY27 guidance. Watch for sequential growth in Huron revenue each quarter through year-end. A Q3 Huron revenue below ₹100 Cr signals ramp-up risk.

  • 3 · Entry-level machine mix evolution and high-end dispatch

    Track the split between entry-level (₹ and units) vs. high-end in Q3 results. If entry-level remains >60% of revenue, the mix is stickier than management admits. High-end dispatch volume and A&D order intake will indicate whether capacity shift toward higher-margin products is real.

The verdict

Jyoti is a **steady execution story with a profitability question mark**—not a step-change turnaround. The order book is real. The capacity expansion is real. But the margin miss in Q2 (21.8% vs 25% guided) is real, and the path to recovery is unproven. Management has reaffirmed all guidance despite the profit decline, which shows discipline; it also shows confidence may be outrunning execution.

The stock is positioned at a valuation reset (-32% from ATH, +76% from lows, above key moving averages). It has room to move either way based on Q3 margin delivery. FII trimming suggests institutions are hedging their bets on the near-term profit recovery.

**For holders:** Hold if you believe H2 margin recovery happens as guided (25% EBITDA). Trim if Q3 consolidated OPM stays below 22%—that would signal the entry-level mix is structural and full-year guidance is at risk. **For new investors:** Wait for Q3 margin confirmation before adding. The order book visibility is valuable, but it does not guarantee profit; growth without margin expansion is just revenue churn.

**The number to track:** Consolidated OPM in Q3. If it rebounds toward 23–24%, the bull case holds. If it stays at 21–22%, the guidance is broken and the stock deserves re-rating lower.

Informational and educational content only. Not investment advice.